Latest Period
Q2 2026
Security Snapshot
Immunic, Inc. - Common Stock, par value $0.0001 per share (IMUX) Institutional Ownership
CUSIP: 4525EP101
13F Institutional Holders and Ownership History from Q2 2019 to Q2 2026
Institutions Reporting
0
Shares (Excl. Options)
0
Price
$0.88
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, par value $0.0001 per share
- Symbol
- IMUX on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 0
- Total 13F value
- $0
- Share change
- -63,821,144
- Value change
- -$70,854,750
- Number of holders
- 0
- Shares outstanding
- 14,280,377
- SEC-reported price per share
- $0.88
- Insider filing price
- $0.88
Latest holder snapshot
4 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- IMUX - Immunic, Inc. - Common Stock, par value $0.0001 per share is tracked under CUSIP 4525EP101.
- 0 institutions reported positions in Q2 2026.
- 19 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 74 to 0 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $70,999,597 to $0.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 0 institutions filings for Q2 2026.
Security key
4525EP101
Latest holder period
Q2 2026
13F holders
0
13D/G owners
19
CIK / CUSIP context first
Open Q2 2026 holders
IMUX full holder history
IMMUNIC, INC. SEC filings
IMMUNIC, INC. company facts
IMMUNIC, INC. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 4525EP101:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
19
Security
IMUX
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Vivo Opportunity Fund Holdings, L.P. | 10% | $17,767,413 | 29,126,906 | Vivo Opportunity Fund Holdings, L.P. | 17 Feb 2026 | |||
| Avidity Partners Management LP | 9.9% | +102% | $15,493,835 | +$10,277,489 | 13,958,410 | +197% | Avidity Partners Management LP | 17 Feb 2026 |
| BIOTECHNOLOGY VALUE FUND L P | 10% | 0% | $8,314,667 | +$2,345,708 | 13,630,601 | +39% | BVF PARTNERS L P/IL | 12 Feb 2026 |
| Commodore Capital LP | 9.9% | $8,143,574 | 13,350,121 | Commodore Capital LP | 17 Feb 2026 | |||
| JANUS HENDERSON GROUP PLC | 10% | +233% | $8,531,675 | +$6,622,427 | 12,016,444 | +347% | JANUS HENDERSON GROUP PLC | 28 Nov 2025 |
| Deep Track Capital, LP | 8.7% | $9,964,980 | 11,454,000 | Deep Track Capital, LP | 17 Feb 2026 | |||
| Trails Edge Capital Partners, LP | 8.7% | $6,986,940 | 11,454,000 | Trails Edge Capital Partners, LP | 17 Feb 2026 | |||
| Adage Capital Management, L.P. | 10% | +422% | $8,697,850 | +$7,537,012 | 10,479,337 | +649% | Adage Capital Management, L.P. | 30 Jun 2025 |
| Nantahala Capital Management, LLC | 8.2% | -18% | $7,057,316 | -$174,188 | 10,378,406 | -2.4% | Nantahala Capital Management, LLC | 31 Dec 2025 |
| Aberdeen Group plc | 6.8% | -19% | $4,399,791 | 8,243,941 | 0% | Aberdeen Group plc | 31 Dec 2025 | |
| Soleus Capital Master Fund, L.P. | 5.5% | $4,143,120 | 6,792,000 | Soleus Capital Master Fund, L.P. | 17 Feb 2026 | |||
| Alyeska Investment Group, L.P. | 4.8% | -23% | $7,345,120 | -$1,354,880 | 6,332,000 | -16% | Alyeska Investment Group, L.P. | 31 Mar 2026 |
| VANGUARD GROUP INC | 4.4% | $4,473,090 | 3,923,763 | The Vanguard Group | 31 Dec 2024 | |||
| Soleus Private Equity Fund III, L.P. | 1.6% | $1,392,934 | 1,580,007 | Soleus Capital Management, L.P. | 30 Sep 2025 | |||
| RTW INVESTMENTS, LP | 1.1% | $1,170,509 | 1,026,762 | RTW Investments, LP | 31 Mar 2025 | |||
| INTEGRATED CORE STRATEGIES (US) LLC | 5.7% | $920,600 | 793,621 | Millennium Management LLC | 29 Apr 2026 | |||
| ORBIMED ADVISORS LLC | 5.3% | $666,037 | 756,860 | OrbiMed Advisors LLC | 30 Jun 2026 | |||
| 683 Capital Management, LLC | 3.4% | -42% | $550,072 | -$8,149,928 | 474,200 | -94% | 683 CAPITAL MANAGEMENT, LLC | 31 Mar 2026 |
| ARMISTICE CAPITAL, LLC | 5% | -50% | $328,030 | -$49,773 | 372,085 | -13% | Armistice Capital, LLC | 30 Sep 2025 |
As of 30 Jun 2026, 0 institutional investors reported holding 0 shares of Immunic, Inc. - Common Stock, par value $0.0001 per share (IMUX). This represents 0% of the company’s total 14,280,377 outstanding shares.
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
29
Latest
Q2 2026
Rows shown
1-25 of 29
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 0 | $0 | -$70,854,750 | $0.88 | 0 |
| 2026 Q1 | 63,951,636 | $70,999,597 | +$17,381,778 | $1.11 | 74 |
| 2025 Q4 | 48,654,047 | $25,965,609 | +$3,658,356 | $0.53 | 58 |
| 2025 Q3 | 42,691,219 | $37,637,800 | -$6,010,022 | $0.88 | 61 |
| 2025 Q2 | 50,178,419 | $35,007,422 | +$6,044,822 | $0.70 | 55 |
| 2025 Q1 | 40,453,267 | $44,092,350 | -$10,908,092 | $1.09 | 63 |
| 2024 Q4 | 51,078,929 | $51,080,793 | -$5,070,929 | $1.00 | 65 |
| 2024 Q3 | 55,990,706 | $92,402,857 | +$4,082,986 | $1.65 | 61 |
| 2024 Q2 | 55,825,550 | $62,078,863 | -$1,856,872 | $1.11 | 57 |
| 2024 Q1 | 57,356,707 | $75,746,429 | +$55,567,381 | $1.32 | 60 |
| 2023 Q4 | 15,140,220 | $22,708,217 | -$4,865,374 | $1.50 | 49 |
| 2023 Q3 | 18,373,010 | $27,006,486 | -$3,552,617 | $1.47 | 53 |
| 2023 Q2 | 20,191,368 | $50,673,312 | -$8,732,751 | $2.51 | 62 |
| 2023 Q1 | 24,789,103 | $36,932,167 | +$1,129,629 | $1.49 | 57 |
| 2022 Q4 | 24,354,230 | $34,040,740 | +$5,454,473 | $1.40 | 59 |
| 2022 Q3 | 17,440,399 | $55,106,794 | -$3,092,179 | $3.16 | 62 |
| 2022 Q2 | 18,260,665 | $63,350,669 | -$15,186,048 | $3.47 | 65 |
| 2022 Q1 | 17,606,263 | $198,949,802 | +$44,387,028 | $11.30 | 78 |
| 2021 Q4 | 13,709,674 | $131,117,717 | +$7,603,275 | $9.57 | 66 |
| 2021 Q3 | 12,872,467 | $113,976,993 | +$30,193,655 | $8.85 | 66 |
| 2021 Q2 | 9,434,902 | $115,673,222 | -$1,395,354 | $12.26 | 56 |
| 2021 Q1 | 9,300,714 | $148,252,917 | -$6,173,953 | $15.94 | 60 |
| 2020 Q4 | 9,727,941 | $148,744,642 | +$11,593,540 | $15.29 | 66 |
| 2020 Q3 | 8,546,270 | $158,699,665 | +$86,090,223 | $18.57 | 64 |
| 2020 Q2 | 4,206,160 | $51,019,563 | +$24,949,305 | $12.12 | 47 |